Indication name: Hepatic
Encephalopathy
Hepatic Encephalopathy – Market outlook,
Epidemiology, Market Forecast and Competitive Landscape Report – 2020 To 2030
(Markets covered: US, Germany, France, Spain, United Kingdom, Italy, Japan
& China.
Hepatic
Encephalopathy, sometimes referred to as portosystemic encephalopathy or PSE, is a
condition that causes temporary worsening of brain function with advanced liver
disease. Hepatic encephalopathy occurs in individuals with damage liver where
toxins in the liver accumulate in the blood and eventually traveling to and
damaging the brain. Although the exact underlying process by which hepatic encephalopathy
develops is unknown, high levels of substances produced by the digestive
breakdown of proteins, such as ammonia, are believed to play a major role.
Epidemiology- Estimated about 5.5 million
people in the United States affected with hepatic encephalopathy.
Competitive landscape of Hepatic
Encephalopathy includes country specific approved as well as pipeline
therapies. Any asset/ product specific designation or review and Accelerated
Approval are being tracked and supplemented with analyst commentary.
KOLs insights of Hepatic Encephalopathy
across 8 MM market from center of Excellence/ Public/ Private hospitals
participated in the study. Insights around current treatment landscape,
epidemiology, clinical characteristics, future treatment paradigm and Unmet
needs.
Hepatic Encephalopathy Market Forecast:
Patient Based Forecast Model (MS. Excel Based Automated Dashboard) which Data
Inputs with sourcing, Market Event and Product Event, Country specific Forecast
Model, Market uptake and patient share uptake, Attribute Analysis, Analog
Analysis, Disease burden and pricing scenario, Summary and Insights.
S. No Asset Company Stage
1 MNK-6105 Mallinckrodt Phase 3
2 FMT Rebiotix Inc. Phase 2
3 AXA1665 Axcella Health, Inc Phase 2
4 Rifaximin Bausch Health Americas, Inc. Phase 2
5 HPN-100 Horizon Pharma Ireland, Ltd., Dublin Ireland Phase 2
No comments:
Post a Comment